vs

Side-by-side financial comparison of Finward Bancorp (FNWD) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $16.5M, roughly 1.3× Finward Bancorp). Finward Bancorp runs the higher net margin — 12.0% vs -165.4%, a 177.5% gap on every dollar of revenue. On growth, Finward Bancorp posted the faster year-over-year revenue change (1.1% vs -25.3%). Finward Bancorp produced more free cash flow last quarter ($9.0M vs $-65.0M). Over the past eight quarters, NEKTAR THERAPEUTICS's revenue compounded faster (0.4% CAGR vs -19.1%).

Finward Bancorp is a U.S.-headquartered regional bank holding company. It offers a full range of retail and commercial banking products and services, including deposit accounts, personal and mortgage loans, small business financing, and wealth management solutions, primarily serving individual customers and small to mid-sized enterprises in its local operating regions.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

FNWD vs NKTR — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.3× larger
NKTR
$21.8M
$16.5M
FNWD
Growing faster (revenue YoY)
FNWD
FNWD
+26.3% gap
FNWD
1.1%
-25.3%
NKTR
Higher net margin
FNWD
FNWD
177.5% more per $
FNWD
12.0%
-165.4%
NKTR
More free cash flow
FNWD
FNWD
$74.0M more FCF
FNWD
$9.0M
$-65.0M
NKTR
Faster 2-yr revenue CAGR
NKTR
NKTR
Annualised
NKTR
0.4%
-19.1%
FNWD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FNWD
FNWD
NKTR
NKTR
Revenue
$16.5M
$21.8M
Net Profit
$2.0M
$-36.1M
Gross Margin
Operating Margin
11.0%
-126.9%
Net Margin
12.0%
-165.4%
Revenue YoY
1.1%
-25.3%
Net Profit YoY
-5.6%
-596.9%
EPS (diluted)
$0.46
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FNWD
FNWD
NKTR
NKTR
Q4 25
$16.5M
$21.8M
Q3 25
$17.4M
$11.8M
Q2 25
$16.6M
$11.2M
Q1 25
$15.5M
$10.5M
Q4 24
$16.3M
$29.2M
Q3 24
$14.9M
$24.1M
Q2 24
$14.6M
$23.5M
Q1 24
$25.3M
$21.6M
Net Profit
FNWD
FNWD
NKTR
NKTR
Q4 25
$2.0M
$-36.1M
Q3 25
$3.5M
$-35.5M
Q2 25
$2.2M
$-41.6M
Q1 25
$455.0K
$-50.9M
Q4 24
$2.1M
$7.3M
Q3 24
$606.0K
$-37.1M
Q2 24
$143.0K
$-52.4M
Q1 24
$9.3M
$-36.8M
Gross Margin
FNWD
FNWD
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
FNWD
FNWD
NKTR
NKTR
Q4 25
11.0%
-126.9%
Q3 25
20.5%
-268.6%
Q2 25
12.7%
-324.2%
Q1 25
4.0%
-425.8%
Q4 24
16.3%
49.2%
Q3 24
2.7%
-142.4%
Q2 24
0.9%
-211.9%
Q1 24
40.6%
-163.7%
Net Margin
FNWD
FNWD
NKTR
NKTR
Q4 25
12.0%
-165.4%
Q3 25
20.1%
-301.3%
Q2 25
12.9%
-372.2%
Q1 25
2.9%
-486.4%
Q4 24
12.9%
24.9%
Q3 24
4.1%
-153.6%
Q2 24
1.0%
-222.9%
Q1 24
36.7%
-170.1%
EPS (diluted)
FNWD
FNWD
NKTR
NKTR
Q4 25
$0.46
$-4.67
Q3 25
$0.81
$-1.87
Q2 25
$0.50
$-2.95
Q1 25
$0.11
$-0.24
Q4 24
$0.50
$-2.07
Q3 24
$0.14
$-2.66
Q2 24
$0.03
$-3.76
Q1 24
$2.17
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FNWD
FNWD
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$174.7M
$89.8M
Total Assets
$2.0B
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FNWD
FNWD
NKTR
NKTR
Q4 25
$15.1M
Q3 25
$41.0M
Q2 25
$43.0M
Q1 25
$38.9M
Q4 24
$44.3M
Q3 24
$30.1M
Q2 24
$27.9M
Q1 24
$48.6M
Stockholders' Equity
FNWD
FNWD
NKTR
NKTR
Q4 25
$174.7M
$89.8M
Q3 25
$165.5M
$85.1M
Q2 25
$154.3M
$-24.2M
Q1 25
$151.8M
$13.7M
Q4 24
$151.4M
$60.7M
Q3 24
$159.6M
$48.9M
Q2 24
$148.6M
$79.7M
Q1 24
$151.6M
$126.7M
Total Assets
FNWD
FNWD
NKTR
NKTR
Q4 25
$2.0B
$280.4M
Q3 25
$2.1B
$301.3M
Q2 25
$2.1B
$207.5M
Q1 25
$2.0B
$256.2M
Q4 24
$2.1B
$303.9M
Q3 24
$2.1B
$308.0M
Q2 24
$2.1B
$343.3M
Q1 24
$2.1B
$396.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FNWD
FNWD
NKTR
NKTR
Operating Cash FlowLast quarter
$9.9M
$-65.0M
Free Cash FlowOCF − Capex
$9.0M
$-65.0M
FCF MarginFCF / Revenue
54.8%
-298.0%
Capex IntensityCapex / Revenue
5.2%
0.1%
Cash ConversionOCF / Net Profit
4.99×
TTM Free Cash FlowTrailing 4 quarters
$10.6M
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FNWD
FNWD
NKTR
NKTR
Q4 25
$9.9M
$-65.0M
Q3 25
$1.2M
$-48.8M
Q2 25
$4.8M
$-45.7M
Q1 25
$-3.8M
$-49.1M
Q4 24
$9.8M
$-46.2M
Q3 24
$-3.7M
$-43.9M
Q2 24
$2.8M
$-37.7M
Q1 24
$-25.0K
$-47.9M
Free Cash Flow
FNWD
FNWD
NKTR
NKTR
Q4 25
$9.0M
$-65.0M
Q3 25
$1.0M
$-48.9M
Q2 25
$4.5M
$-45.8M
Q1 25
$-4.0M
$-49.1M
Q4 24
$6.7M
$-46.6M
Q3 24
$-4.2M
$-44.6M
Q2 24
$1.1M
$-37.9M
Q1 24
$-736.0K
$-48.0M
FCF Margin
FNWD
FNWD
NKTR
NKTR
Q4 25
54.8%
-298.0%
Q3 25
6.0%
-414.5%
Q2 25
27.0%
-409.6%
Q1 25
-25.7%
-469.0%
Q4 24
41.2%
-159.9%
Q3 24
-28.5%
-184.9%
Q2 24
7.6%
-161.3%
Q1 24
-2.9%
-222.0%
Capex Intensity
FNWD
FNWD
NKTR
NKTR
Q4 25
5.2%
0.1%
Q3 25
0.9%
1.0%
Q2 25
1.7%
0.3%
Q1 25
1.2%
0.0%
Q4 24
18.8%
1.6%
Q3 24
3.4%
2.8%
Q2 24
11.2%
0.8%
Q1 24
2.8%
0.7%
Cash Conversion
FNWD
FNWD
NKTR
NKTR
Q4 25
4.99×
Q3 25
0.34×
Q2 25
2.22×
Q1 25
-8.37×
Q4 24
4.66×
-6.36×
Q3 24
-6.15×
Q2 24
19.23×
Q1 24
-0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons